Roy Pettipher, PhD
Dr. Pettipher has over 25 years experience in anti-inflammatory drug discovery having previously worked at Pfizer and Wellcome Laboratories. At Oxagen Ltd, he was involved in the initiation and management of its anti-inflammatory CRTH2 antagonist program which has yielded a clinical candidate, currently in Phase IIb trials.
He has extensive experience in drug discovery and non-clinical and clinical development, most recently in asthma and related allergic conditions. He holds a degree in Pharmacology from the University of Bath, a PhD in Pharmacology from the University of London and an MBA from Imperial College, London.